Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Open Access
- 30 March 2020
- preprint content
- other
- Published by Cold Spring Harbor Laboratory
Abstract
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ.Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.Trial registration: URL: https://www.clinicaltrials.gov/. The unique identifier: ChiCTR2000029559.Keywords
This publication has 19 references indexed in Scilit:
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case reportToxicology Reports, 2019
- Hydroxychloroquine Retinal ToxicityNew England Journal of Medicine, 2019
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adultsRheumatology, 2017
- Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivityCell Biochemistry and Function, 2016
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology, 2015
- Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseasesJournal of Antimicrobial Chemotherapy, 2015
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004